[關(guān)鍵詞]
[摘要]
目的 探討不同劑量阿替普酶聯(lián)合瑞舒伐他汀治療急性缺血性腦卒中的療效及安全性。方法 收取2010年1月至2015年12月于西電集團(tuán)醫(yī)院就診的急性缺血性腦卒中患者82例作為研究對(duì)象,采用隨機(jī)數(shù)字表法將其分為觀察組與對(duì)照組各41例,觀察組給予標(biāo)準(zhǔn)劑量阿替普酶(0.9 mg/kg)聯(lián)合瑞舒伐他汀治療,對(duì)照組給予低劑量阿替普酶(0.6 mg/kg)聯(lián)合瑞舒伐他汀治療。對(duì)兩組患者治療前后神經(jīng)系統(tǒng)功能損傷、血脂變化情況、臨床療效、患者恢復(fù)情況及不良反應(yīng)進(jìn)行考察。結(jié)果 治療后兩組患者NIHSS評(píng)分及CSS評(píng)分均有所下降,與治療前相比差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。同時(shí)間點(diǎn)兩組間差異不顯著;治療后兩組患者總膽固醇(TC)及低密度脂蛋白(LDL)明顯下降,差異較治療前有統(tǒng)計(jì)學(xué)意義(P<0.05),觀察組明顯低于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。觀察組總有效率與對(duì)照組比較差異無顯著性。治療后兩組MRS評(píng)分均較治療前下降,且隨時(shí)間逐漸降低,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。觀察組治療后MRS評(píng)分低于對(duì)照組,自治療后14d開始有統(tǒng)計(jì)學(xué)差異(P<0.05)。兩組不良反應(yīng)發(fā)生率比較差異無顯著性。結(jié)論 標(biāo)準(zhǔn)劑量阿替普酶聯(lián)合瑞舒伐他汀與小劑量阿替普酶相比療效及安全性相當(dāng),但對(duì)于改善患者血脂水平及恢復(fù)情況更具優(yōu)勢(shì),因此值得臨床推廣應(yīng)用。
[Key word]
[Abstract]
Objective To investigate the efficacy and safety of different doses of atorvastatin combined with rosuvastatin in the treatment of acute ischemic stroke. Methods Totally 82 patients with acute ischemic stroke accepted in Xi'an XD Group Hospital from January 2010 to February 2015 were selected and randomly divided into observation group and control group with 41 cases in each group. Patients in observation group were given standard dose of rt-PA (0.9 mg/kg) combined with rosuvastatin, and patients in control group were given low dose of rt-PA (0.6 mg/kg) combined with rosuvastatin. Nervous system injury, blood lipid before and after treatment, clinical effect, recovery, and adverse reactions of two groups were observed and compared. Results NIHSS and CSS scores of two groups after treatment were obviously lower than those before treatment with statistically significance (P<0.05), but difference between two groups of same time had no statistical significance. TC and LDL were decreasing after treatment, which had obvious difference compared to those before treatment. And observation group was lower than control group (P<0.05). Total efficacy of two groups had no difference. MRS scores of two groups were decreased with time, and MRS score of observation group was lower than that of control group with statistically difference after 14 d treatment (P<0.05). Adverse reaction rate of two groups had no statistical difference. Conclusion Different doses of rt-PA combined with rosuvasdtatin have similar effect and safety, but standard dose has better blood lipid level and recovery, which is worth clinical application.
[中圖分類號(hào)]
[基金項(xiàng)目]